For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness and safety outcomes.

A clot-busting drug recently approved to treat acute ischemic strokes (AIS) that can be delivered quickly works as well as a decades-old medication used by most hospitals in the U.S. and could hold ...

Tenecteplase provides comparable safety and effectiveness outcomes for acute ischemic stroke as alteplase, new research ...

The activity and sterility of reconstituted alteplase solution and the effectiveness of an alteplase dose-escalation protocol for the clearance of midlinecatheter and central-venous-access device ...

Recombinant human prourokinase is noninferior to alteplase in acute ischemic stroke, with symptomatic intracranial hemorrhage and major bleeding decreased.

A new clot-busting drug for stroke works as well as a decades-old drug Patients given tenecteplase had similar outcomes to ...

Acute ischemic stroke, which occurs due to a blockage in cerebral blood flow, requires prompt intervention with thrombolytic ...

Intravenous alteplase (recombinant tissue plasminogen activator) is restricted for use within 3 h from stroke onset by marketing authorizations. Some patients are treated beyond this approved time ...

And now, research shows that tenecteplase works just as well as the standard clot-busting drug alteplase used to treat strokes, according to findings published recently in JAMA Network Open.

The researchers observed no significant differences between tenecteplase and alteplase in terms of effectiveness or safety outcomes for the overall cohort after adjustment for covariates.

No significant difference seen in terms of effectiveness or safety outcomes, including functional independence at discharge. (HealthDay News) — For patients with ischemic stroke, tenecteplase ...